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Introduction
Medication-related problems are common in older adults 
and are associated with increased morbidity, adverse drug 
events (ADEs), extended hospital stays and increased mor-
tality.1–3 Potentially inappropriate prescribing (PIP) can 
introduce the risk of an ADE which has the potential to out-
weigh the drug’s clinical benefit, particularly when a safer or 
more effective alternative treatment option is available.4 The 
term ‘potentially’ is used, as the physician may have consid-
ered the potential negative consequences of prescribing the 
drug as well as alternative treatment options for that patient 
but chose to proceed with a given approach.5 Recent 
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evidence indicates that the prevalence of PIP in older adults 
in primary care is high, with nationally representative esti-
mates in Ireland, Northern Ireland and the United Kingdom 
at 36%, 34% and 29%, respectively, using an explicit meas-
ure of inappropriate prescribing.6–8 Curtis et al. conducted a 
retrospective cohort study using a national sample of pre-
scription drug claims for patients aged over 65 years enrolled 
with a pharmaceutical benefit manager in the United States. 
The study highlighted that more than one in five patients 
filled a prescription for one or more drugs of concern based 
on the Beers’ revised list of drugs to be avoided in elderly 
populations.9
A number of screening tools have been developed to 
assess the appropriateness of prescribing, which use an 
explicit (criterion-based) or implicit (judgement-based) 
approach.3 Explicit tools are usually developed from pub-
lished literature, multidisciplinary expert panels and consen-
sus validation methods. The potential drawbacks of using 
explicit criteria include a lack of transparency of the litera-
ture used, reliability of the consensus techniques and con-
flicts of interest of the expert panels.10 Explicit criteria 
include the Beers and STOPP/START (Screening Tool of 
Older Persons Prescriptions/Screening Tool to Alert doctors 
to Right Treatment) criteria.4,11 Beers criteria contain several 
medicines that are either not prescribed or not available in 
most European drug formularies, thus its application in an 
European Union (EU) setting is limited.12 The STOPP crite-
ria comprise a physiological system–based screening tool 
designed for use in Europe. It aims to identify potentially 
inappropriate medicines (PIMs) by listing explicit rules for 
avoidance of particular medicines in older people. In addi-
tion, potential prescribing omissions (PPOs) have been iden-
tified by an accompanying screening tool known as START.13
In implicit approaches, healthcare professionals use 
information from the patient and published reviews to assess 
the appropriateness of medicines.3,14 The Medication 
Appropriateness Index (MAI) is an example of a validated 
implicit tool.15 It consists of 10 criteria that relate to a num-
ber of different prescribing domains, for example, indica-
tion, effectiveness, dose, duration, correct directions, 
practical directions, drug–drug interactions, drug–disease 
interactions, duplication and cost. The tool generates a 
weighted score (ranging from 0 to 18) per drug that serves 
as a measure of medication appropriateness. A higher score 
indicates an increased level of inappropriateness.15 The 
application of implicit tools is time-consuming, depends on 
the users knowledge and in addition, the MAI does not 
address under-prescribing.3
Across transitions of care, evidence indicates that phar-
macists play a significant role in gate-keeping medication 
appropriateness, with respect to quality and safety of pre-
scribing.16 Research suggests that pharmacists can reduce 
PIP and adverse health outcomes in patients across a range of 
healthcare settings by utilising explicit and implicit screen-
ing tools systematically.17–20
To date, evidence has been collated on various pharma-
cist-led interventions to reduce PIP across healthcare set-
tings. However, no review has summarised the totality of 
evidence regarding the impact of pharmacist-led interven-
tions to reduce PIP in older adults specifically in primary 
care.
Therefore, the aim of this review is to evaluate studies of 
pharmacist-led interventions on medication prescribing 
among community-dwelling older adults receiving primary 
care to identify the components of a successful intervention.
Methods
Standardised reporting guidelines
This systematic review adhered to the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) 
standardised reporting guidelines to ensure the standardised 
conduct and reporting of the research.21 The PRISMA check-
list is provided in Appendix 3.
Study identification
An electronic search of the literature was conducted using 
the following databases from inception to December 2015: 
PubMed, Embase, Cumulative Index to Nursing and Allied 
Health Literature (CINAHL), MEDLINE (through Ovid), 
Trip, Centre for Reviews and Dissemination databases, 
Cochrane Database of Systematic Reviews, ISI Web of 
Science, ScienceDirect, ClinicalTrials.gov, metaRegister of 
Controlled Trials (mRCT), ProQuest Dissertations & Theses 
Database (theses in Great Britain, Ireland and North 
America). A combination of the following keywords and 
MeSH terms were used: ‘primary care’ or ‘primary health 
care’ or ‘outpatient care’ AND ‘prescribing’ or ‘prescription’ 
and ‘aged’ or ‘middle aged’ or ‘elderly’ AND ‘pharmacist’ or 
‘pharmaceutical care’. There were no date or language 
restrictions on the searches. A list of the search strategies for 
each database is provided in Appendix 1. The references of 
final search results were handsearched along with hand-
searching the references of some already published reviews 
and the authors’ own records.17,22
Study selection
Studies were included if they met the following inclusion 
criteria:
Study design. All randomised (cluster) controlled trials 
(RCTs), quasi-RCTs, controlled before and after studies 
and interrupted time series (ITS) designs were included.
Population. Community-dwelling older adults aged 
≥65 years. Studies based on nursing home populations 
were excluded. A recent Cochrane Review published by 
Alldred et al (2016).19 focused on interventions to 
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optimise prescribing for older patients in care homes. In 
all 8 out of the 12 studies retrieved were pharmacist-
led.19 Therefore, it was decided that this question had 
already been answered for patients in this particular 
setting.
Intervention. Pharmacist-led interventions were defined 
as any intervention where the pharmacist had the lead role 
in an intervention designed to reduce PIP or improve 
medication appropriateness in primary care. The compar-
ison group was usual care or other active interventions 
not focused on medication appropriateness.
Outcome. The primary outcome measure was the change 
in prescribing appropriateness using a validated explicit 
or implicit screening tool for the detection of PIP, that is, 
Beers criteria, STOPP/START, MAI. Secondary out-
comes included any clinical or patient self-reported out-
comes (e.g. quality of life, patient satisfaction).
Studies were excluded if they were currently ongoing, if 
there was a lack of reply from the author for supplementary 
information and if they only carried out an economic analy-
sis. A list of the excluded studies reviewed with reasons for 
exclusion is provided in Appendix 2.
Study selection and data extraction
Two reviewers (D.O.R. and K.W.) independently read the 
titles and/or abstracts of the identified papers and eliminated 
irrelevant studies. Studies considered to be eligible for inclu-
sion were read in full and their suitability for inclusion was 
determined independently by two reviewers (D.O.R. and 
K.W.). Disagreements were managed by consensus. 
However, if this was not successful, consensus was sought 
by a third reviewer (S.B.).
Data were extracted based on study design and setting, 
patient demographics and inclusion criteria, details of the 
intervention and comparison, length of follow-up and out-
come measures used. Authors were contacted to provide sup-
plementary information when insufficient data were provided 
in the study. The authors of five studies were contacted for 
further information having read their titles and abstracts. 
Three replied; however, none of these studies fulfilled the 
inclusion criteria. Despite emailing the authors of the other 
two studies on two different occasions, we received no reply. 
Therefore, these studies were not included.
Assessment of risk of bias
Two reviewers (D.O.R. and R.G.) independently assessed 
the risk of bias for ITS using the Effective Practice and 
Organisation of Care (EPOC) risk of bias criteria and for 
RCTs using the Cochrane Collaboration’s tool for assessing 
risk of bias.23,24 In any case of disagreement, consensus was 
reached with a third reviewer (K.W.).
Results
A total of 2193 studies were identified following removal of 
duplicates, and five additional studies were located from 
handsearching references. A PRISMA flowchart (Figure 1) 
describes the flow of studies in the review. A total of 58 full-
text studies were assessed for eligibility. At the end of the 
process, five studies were eligible for inclusion in the sys-
tematic review. Of the five included studies, three were con-
ducted in the United States, one in Europe and one in New 
Zealand.25–29
The characteristics of the five included studies are sum-
marised in Table 1.
Characteristics of included studies
Four of the studies involved a pharmacist carrying out a med-
ication review and providing feedback to patients or their 
family physician.25–28 One study evaluated the effect of a 
computerised tool that alerted pharmacists at the point of dis-
pensing when older patients were newly prescribed PIMs.29
Bryant et al. involved pharmacists carrying out clinical 
medication reviews and providing feedback to the patient’s 
physicians, while the control group received usual care which 
was not defined. A total of 269 patients were enrolled in the 
intervention group. The MAI score improved more in the 
intervention group than in the control group (mean change in 
MAI score −2.0 in the intervention group; −0.3 in the control 
group, p < 0.001). There were more medicines started in the 
control group than the intervention group (p < 0.0001), while 
there were more dosage reductions and medicine switches in 
the intervention group than in the control group (p = 0.037).25
Hanlon et al. evaluated the effect of a pharmacist-led 
review of patient’s medical charts, followed by a clinical rec-
ommendation to the family physician in 105 cases. The 
researchers also provided compliance strategies to the 
patients. Patients in the control group had their medications 
reviewed by a clinical nurse; however, the clinical pharma-
cist had no interaction with the patients or their clinicians 
during the study period. The MAI score improved more in 
the intervention group than in the control group (mean 
change in MAI score −4.9 in the intervention group; −0.9 in 
the control group, p < 0.001). There was no significant differ-
ence between groups regarding ADEs, p = 0.19, or Veterans 
Affairs (VA) medicines prescribed, p = 0.83.26
Taylor et al. examined the effect of a pharmacist interven-
tion that provided medication education to patients and ther-
apeutic recommendations to their family physicians 
following a medication review in 33 older adults. A pharma-
cist evaluated the pharmacotherapy of each patient in the 
control group; however, no recommendations were reported 
to the patient or their physician. The percentage of inappro-
priate prescriptions decreased in all 10 MAI domains in the 
intervention group and increased in five domains in the con-
trol group. Clinical outcomes such as hypertension, diabetes 
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mellitus, dyslipidaemia, anticoagulation, hospitalisations 
and emergency department (ED) admissions were reported. 
Compared to the control group, the intervention group was 
more likely to have controlled blood pressure (p = 0.001), 
HbA1c (p = 0.001), low-density lipoprotein (LDL) choles-
terol (p = 0.001) and international normalised ratio (INR) 
(p = 0.048). There were fewer hospitalisations (2 vs 11, 
p = 0.003) and ED visits (4 vs 6, p = 0.044) in the intervention 
group compared to the control group.27
Richmond et al. developed pharmaceutical care plans 
among pharmacists and family physicians. The pharmaceutical 
care model involved pharmacists carrying out medication 
reviews and collaborating with physicians, patients and carers 
to identify issues with compliance and adverse drug reactions. 
It was hypothesised that the review process would also serve to 
encourage the prescribing of generic medicines and reduce 
health costs. Following this, pharmacists conducted monthly 
medication reviews with feedback to the physicians. The usual 
care group consisted of patients within each of the five primary 
care trusts (PCTs) on a waiting list to receive pharmaceutical 
care. A total of 551 participants completed the study. Results 
demonstrated that the pharmaceutical care model did not affect 
the appropriateness of prescribing (mean change in UK-MAI 
score from baseline to the end of the intervention was −0.26, 
p > 0.05). Also, the pharmaceutical care model was not associ-
ated with any of the reported serious adverse events.28
Figure 1. A PRISMA flowchart outlining the procurement of five included studies.
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Finally, Raebel et al. estimated the effect of a computer-
ised tool that alerted pharmacists at the point of dispensing 
when older patients were newly prescribed PIMs. Pharmacists 
and physicians collaborated to develop a targeted medication 
list for the intervention group based on the Beers, Zhan and 
Kaiser Permanente Care Management Institute lists of medi-
cations to be avoided in older people.30–32 The intervention 
group consisted of 29,840 patients. When a patient ran-
domised to the intervention group was prescribed a new PIM, 
the pharmacist was notified via a medication alert generated 
from an electronic database. Pharmacists were required to 
complete a note on a standard intervention template before 
printing a label to dispense the prescription. Pharmacists were 
then instructed to telephone the prescribing physician to sug-
gest alternatives. Patients in the control group received medi-
cation prescribing and dispensing according to usual clinical 
practice. When medications were dispensed, monitoring and 
patient management proceeded according to the prescriber’s 
usual procedures. Over the course of the study, 1.8% of inter-
vention group patients versus 2.2% of control group patients 
had a newly prescribed PIM (p = 0.002). The relative risk 
reduction (RRR) and absolute risk reduction (ARR) were 
16% and 0.3%, respectively. The dispensing rates for amitrip-
tyline (p < 0.001, RRR 37%) and diazepam (p = 0.02, RRR 
21%) also differed significantly between groups.29
The appropriateness of sample sizes was addressed by 
Hanlon et al.26 and Richmond et al.28 Taylor et al.27 and 
Raebel et al.29 did not carry out a sample size calculation. 
Finally, Bryant et al.25 calculated the sample size based on 
the quality-of-life tool, the SF-36; however, it is unclear how 
many physicians were enrolled in each arm of the study.
Characteristics of the pharmacist’s 
interventions
The characteristics of the criteria applied, healthcare profes-
sionals involved in each study and details of the pharmacist 
interventions are summarised in Table 2. The MAI criteria 
were used in four of the studies.14,25–28 In the Raebel et al.29 
study, the Beers criteria and Zhan criteria were used.30–32 
According to Richmond et al.28 and Raebel et al.,29 pharma-
cists did not have access to medical notes. A medication 
review was conducted in four studies.25–28 In two studies, 
Hanlon et al.26 and Taylor et al.27 involved pharmacists provid-
ing patients with written educational materials as part of the 
intervention. Pharmacists in four of the studies provided feed-
back to the physicians orally or in the written format.25–27,29 
Two of the studies provided feedback via both methods of 
communication.26,27 It is not clear from the Richmond et al. 28. 
study how feedback was communicated to physicians. Finally, 
one study involved an educational meeting with physicians.28
Results of the risk of bias assessment
The results of the risk of bias are presented in Tables 3 and 4. 
Common sources of bias included inadequate sample size, T
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performance bias and spectrum bias. Overall, the authors 
considered four of the five studies to be at high risk of bias.
Synthesis method
Due to the heterogeneity of the interventions and outcome 
measures reported, a narrative synthesis was carried out.
Discussion
Statement of principal findings
This systematic review examined the impact of pharmacist-
led interventions on appropriateness of prescribing in older 
adults in primary care. Interventions across the five studies 
consisted of structured medication reviews or computer 
alerts. Three of the five studies reported an improvement in 
the MAI score in the intervention group compared to the 
control group.25–27 Raebel et al.29 reported a reduction in 
newly dispensed PIMs. Richmond et al.28 reported that 
pharmaceutical care undertaken by community pharmacists 
did not significantly change the appropriateness of pre-
scribing in older patients. One of the limitations from this 
study was that the pharmacists were unable to gather 
detailed clinical records for patients. This may have led to 
an underestimation of the true MAI score.28 In three 
studies, pharmacists had access to the patients’ medical 
notes.25–27 This may have impacted on the nature and scope 
of the medication review by pharmacists. Another limita-
tion was that the pharmacists reported difficulties in access-
ing patients and physicians in order to prepare and discuss 
the pharmaceutical care plan. This was despite the fact that 
joint collaborative training on pharmaceutical care was 
provided to pharmacists and physicians.28 The two studies 
that involved pharmacists providing patients with written 
education materials may have further improved their under-
standing of and compliance with medicines.26,27 In the 
study by Bryant et al.25, the medication review was con-
ducted in the pharmacy or at the patient’s home. Although 
the MAI score improved more in the intervention group 
than in the control group, approximately 40% of the 
pharmacist recommendations were not implemented by the 
physicians. It is not known whether the non-implementa-
tion was due to the physician–pharmacist relationship or 
whether there were other barriers involved.25 According to 
Raebel et al.29, the absolute difference in dispensing num-
bers between intervention and control groups was minimal. 
This was despite the fact that pharmacists and physicians 
collaborated to develop a list of medicines for the interven-
tion, specific intervention guidelines and patient counsel-
ling scripts. The study highlights the difficulty in modifying 
prescribing behaviour even though the intervention was 
fully advocated by the physicians.29 Finally, in the study by 
Hanlon et al., the target population was elderly male veter-
ans. This may impact on the generalisability of the study 
findings.26
Clinical significance of MAI change
In the studies carried out by Hanlon et al.26 and Taylor et al.,27 
the authors conclude that the clinical significance of the 
change in MAI remains unclear and highlight this as a poten-
tial limitation. Bryant et al.25 suggest that further research be 
carried out to determine the relationship between the MAI 
and hospitalisation rates. Finally, in the Richmond et al.28 
study, the pharmaceutical care model carried out by pharma-
cists did not significantly change the appropriateness of pre-
scribing or quality of life in older people.
A narrative review identified seven studies that evalu-
ated the predictive validity of the MAI in relation to various 
health outcomes.14 Three studies involved VA outpatients 
or VA medical centres across the United States.33–35 In these 
studies, higher MAI scores were significantly associated 
with unscheduled ambulatory or ED visits and inadequate 
blood pressure control, ADEs using modified MAI scores 
and adverse drug reactions by drug–disease interaction 
criteria.33–35
Results in the context of the current literature
A systematic review by Kaur et al. evaluated various inter-
ventions and strategies to reduce inappropriate prescribing in 
Table 3. Methodological quality of RCT studies included in the review.
Author Selection bias Performance 
bias
Detection 
bias
Attrition 
bias
Reporting 
bias
Other 
bias
Risk of 
bias
Random 
sequence 
generation
Allocation 
concealment
Blinding of 
participants and 
personnel
Blinding of 
outcome 
assessment
Incomplete 
outcome 
data
Selective 
outcome 
reporting
Other 
sources 
of bias
Overall 
risk of 
bias
Bryant et al.25 High risk High risk Unclear Low risk High risk Low risk Unclear High
Hanlon et al.26 Low risk Unclear High risk Low risk Low risk Low risk High risk High
Raebel et al.29 Low risk Unclear Low risk Unclear Low risk Low risk Unclear Unclear
Taylor et al.27 Unclear Unclear Unclear Unclear Low risk Low risk High risk High
RCT: randomised control trial.
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older people in primary and secondary care settings. The 
review highlighted that pharmacist interventions were suc-
cessful in reducing inappropriate prescribing. Other interven-
tions that demonstrated positive effects on prescribing 
included computerised support systems, geriatrician’s ser-
vices and multidisciplinary team work. However, there were 
mixed responses for educational interventions aimed at 
improving inappropriate prescribing due to the variability in 
assessment methodologies. The effect of regulatory policies 
as an intervention was also variable.36 A further narrative 
review appraised prospective and intervention studies that 
focused on the use of PIMs in community-dwelling older 
adults. Intervention studies that were included aimed to 
change the prescribing patterns of physicians. The majority of 
included studies focused on the prevalence of PIMs. Several 
others analysed the relationship between PIMs and falls, cog-
nitive function, sleep and quality of life. This narrative review 
recommends more collaborative multidisciplinary team 
approaches that include pharmacists to reduce the use of 
PIMs. It also suggests that mixed-methods research could 
enhance the quality of interventions to address PIM use.22 A 
Cochrane Review examined 12 intervention studies including 
pharmacist-led studies aimed at improving appropriate poly-
pharmacy for older people across healthcare settings.17 In 
hospital settings, pharmacists provided pharmaceutical care 
in outpatient clinics and inpatient departments. In primary 
care, pharmacist interventions included medication reviews 
with feedback to physicians and medicine education to 
patients. Finally, in nursing homes, pharmacists worked with 
other healthcare professionals on case conferences and pro-
vided education to staff members. A drug management ser-
vice was also provided. The post-intervention results 
demonstrated a mean difference of −3.88 (95% confidence 
interval (CI) −5.40 to −2.35) in the change in MAI score in 
favour of the intervention group compared with the control 
group across the five studies. This updated review published 
in 2014 was based on a previous Cochrane Review carried 
out by the same authors. It included two additional studies 
from the previous review.17
A review by Castelino et al. evaluated 12 interventions 
involving pharmacists that focused on reducing inappropri-
ate prescribing in older adults across different healthcare set-
tings. The selected studies highlighted pharmacists working 
independently or as part of multidisciplinary healthcare 
teams. The services provided by pharmacists commonly 
involved some form of medication review, highlighting the 
important role that pharmacists play in optimising medica-
tion use for this group of patients.18
The current systematic review has highlighted that phar-
macist-led interventions involving access to medical notes 
and medication reviews conducted in physician practices 
with feedback to physicians may improve prescribing appro-
priateness in community-dwelling older adults. The findings 
are broadly in-keeping with other reviews including a recent 
systematic review with meta-analysis conducted to determine T
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the effectiveness of pharmacist interventions to reduce PIP in 
older adults admitted to hospital. The review concluded that 
pharmacists carrying out medication reviews as part of multi-
disciplinary patient care teams may improve the quality of 
prescribing in older hospitalised patients.17,20,22,36
In addition, the findings are consistent with the evidence 
highlighted that the quality of prescribing for older people in 
primary care could benefit from pharmacist–physician 
collaboration.
Clinical implications and areas for further 
research
This review has implications for clinical practice and future 
research, in particular, with respect to the emerging role that 
pharmacists play in moderating medication appropriateness 
in primary care.
There is a growing need for improved collaboration 
between physicians and pharmacists in order to optimise pre-
scribing practices in primary care. Collaborative multidisci-
plinary models can improve the care of older adults with 
chronic multimorbidities.37 The PINCER trial is an example 
of such a model. It highlighted the benefit of a pharmacist-led 
intervention in general practices in the United Kingdom. The 
practices were cluster randomised to a pharmacist-led infor-
mation technology intervention group or a control group. 
This trial demonstrated that the PINCER intervention was 
effective at reducing medication errors in general practice.38 
Schmader et al. demonstrated that compared with usual care, 
inpatient and outpatient geriatric evaluation and management 
programmes involving pharmacists reduced suboptimal pre-
scribing in frail elderly patients. The outpatient geriatric 
teams also reduced serious adverse drug reactions.39
The diverse range of outcome measures used in studies of 
prescribing appropriateness has made it difficult to make 
firm conclusions in this field. Ideally, prescribing outcome 
measures should be linked to important clinical outcomes 
such as morbidity or mortality. A pan-European study is cur-
rently underway and may add clarity to this issue: The 
OPERAM (Optimising thERapy to prevent Avoidable hospi-
tal admissions in the Multimorbid elderly) study aims to 
reduce the rates of over- and under-prescribing of medica-
tions among multimorbid older European adults. While PIP 
is one measure among others at measuring optimal prescrib-
ing, there is an underreporting of medication errors in the 
literature. One major component of this large multi-centre 
randomised clinical trial will be the use of a sophisticated 
software tool to optimise medication therapy and to deter-
mine whether the applied intervention can improve clinical 
outcomes such as drug-related admissions (DRAs), human-
istic outcomes such as quality of life and reduce healthcare 
costs (https://operam2020.tp21.com).
Educational outreach interventions or ‘academic detail-
ing’ provided by pharmacists (or other clinicians) to physi-
cians in primary care is an area for further research. The 
term ‘academic detailing’ was coined by Jerry Avorn, MD, 
over 30 years ago.40 Clinical educators, who are usually 
pharmacists, nurses or physicians, are trained to provide 
accurate, balanced, non-commercial and up-to-date synthe-
sis of the best clinical evidence in an engaging format with 
healthcare physicians.40 Information highlighted to physi-
cians often includes recommendations about alternative 
treatment regimens or non-pharmacological interventions 
where appropriate. These recommendations are designed to 
complement the clinical judgement of a physician and not to 
replace it.41 This evidence-based strategy has been shown to 
be an effective means of changing physician behaviour and 
improving patient care.42 For example, a pharmacist-led 
intervention comprising academic detailing demonstrated 
an improvement in statin prescribing in high-risk patients in 
primary care.43
There is a dearth of research examining the cost-benefit 
analysis of pharmacist-led interventions to improve prescrib-
ing patterns in healthcare. Cowper and colleagues26,44 con-
ducted a cost analysis of a previously reported RCT. The 
total cost of the clinical pharmacist intervention was US$120 
per patient per year. This intervention was a cost-effective 
means at improving prescribing among elderly outpatients.44 
In the PINCER trial, the cost per error avoided was estimated 
by incremental cost-effectiveness analysis. The pharmacist-
led intervention had a 95% probability of being cost-effec-
tive at various time points throughout the trial.38 The 
economic benefits of using validated screening tools in pri-
mary care are currently limited and require further research.
Strengths and weaknesses
This is the first systematic review to focus specifically on the 
impact of pharmacist-led interventions on prescribing appro-
priateness in older adults in primary care. An explicit and 
robust methodology was applied to identify and synthesise 
the study findings. However, the findings of the review need 
to be interpreted in the context of the study limitations. First, 
the methodological quality of the studies was poor overall, 
limiting the generalisability of the findings. Second, despite 
applying a comprehensive search strategy, only five studies 
were eligible for inclusion in the review. Third, the lack of 
standardised reporting across studies limited the statistical 
pooling of data. Moreover, three studies reported an improve-
ment in the MAI score for the intervention group compared 
to the control group; however, the effect sizes are small 
which highlights the need for further research to assess the 
impact of pharmacist-led interventions in primary care. 
Furthermore, the clinical impact of reducing surrogate mark-
ers such as the MAI remains unknown and requires further 
investigation. However, one of the aims of the OPERAM 
study is to link prescribing outcome measures with clinical 
outcomes such as hospital admissions. Finally, large cluster-
RCTs that are methodologically robust and have a long dura-
tion of follow-up are needed to address patient-focused 
10 SAGE Open Medicine
outcomes. In addition, reviews on the appropriateness of pre-
scribing are warranted among other vulnerable populations 
including paediatric patients, drug users and prisoners.
Conclusion
This review concludes that pharmacist-led interventions 
involving access to medical notes and medication reviews 
conducted in physician practices with feedback to physicians 
may improve prescribing appropriateness in community-
dwelling older adults. Interventions where computer alerts 
that help to inform pharmacists of PIMs may also improve 
prescribing appropriateness. However, it is unclear if these 
interventions result in clinically significant improvements in 
patient outcomes. Furthermore, high-quality research should 
be conducted to explore the generalisability of these inter-
ventions. Finally, the role of a pharmacist working as part of 
a multidisciplinary primary care team requires further inves-
tigation to optimise prescribing in this group of patients.
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Appendix 1. Databases and search terms applied.
Database Search terms applied
CINAHL AGED OR aged, 65 and over OR middle aged OR elderly AND Primary care OR primary health care OR 
community AND Pharmacist* AND Prescription OR prescribing
ClinicalTrials.gov (pharmacist or pharmacists) AND (prescribing OR prescription) AND (inappropriate OR strategy OR 
strategies OR improving OR improve OR optimise OR optimize) AND (primary care OR primary health 
care OR community OR outpatient care) | Adult, Senior
Cochrane Database 
of Systematic 
Reviews
‘aged’ or ‘aged, over 65’ or ‘middle aged’ or ‘elderly’ AND prescribing or prescription or ‘inappropriate 
prescribing’ AND ‘primary care’ or ‘primary health care’ or ‘outpatient care’ or ‘community’ AND 
pharmacist* or ‘pharmaceutical care’ or pharmacist* intervention
Embase ‘aged’ OR ‘aged’ OR ‘middle aged’ OR ‘middle aged’ OR ‘aged, over 65’ OR ‘elderly’ OR ‘elderly’ AND
‘primary care’ OR ‘primary health care’ OR ‘outpatient care’ AND prescribing OR prescription* AND
pharmacist* OR ‘pharmaceutical care’
MEDLINE (through 
Ovid)
(prescribing or prescription) AND (aged or middle aged or elderly) AND (primary care or primary health 
care or elderly care or outpatient care) AND (pharmacist* or pharmaceutical care)
metaRegister of 
Controlled Trials 
(mRCT)
(pharmacist or pharmacists) AND (prescribing OR prescription) AND (inappropriate OR improving OR 
improve OR optimise OR optimize) AND (primary care OR primary health care OR outpatient care OR 
community OR general practice)
ProQuest 
Dissertations & 
Theses
(aged or elderly OR ‘middle aged’) AND (‘primary care’ or ‘primary health care’ OR community or 
‘outpatient care’) AND (prescribing or ‘drug prescribing’ OR prescription* or ‘drug prescription*’) AND 
(pharmacist* or clinical pharmacist* OR ‘pharmaceutical care’ OR ‘pharmacy intervention’ or ‘clinical 
intervention’ OR ‘pharmacist intervention’ or ‘clinical pharmacist intervention’)
PubMed (((‘primary care’ or ‘primary health care’ or ‘outpatient care’))) AND ((prescribing or prescription*))) AND 
((‘aged’ or ‘middle aged’ or elderly))) AND ((pharmacist* or ‘pharmaceutical care’))
ScienceDirect aged OR ‘middle aged’ OR ‘elderly’ AND ‘primary care’ OR ‘primary health care’ OR community OR 
‘outpatient care’ AND prescribing OR prescription* OR ‘appropriate prescribing’ OR ‘inappropriate 
prescribing’ OR ‘potentially inappropriate prescribing’ AND ‘clinical pharmacist’ OR pharmacist* OR 
‘pharmaceutical care’ OR ‘pharmacy intervention’ or ‘clinical intervention’ OR ‘pharmacist intervention’ 
or ‘clinical pharmacist intervention’ (All Sources (Medicine and Dentistry, Nursing and Health Professions, 
Pharmacology, Toxicology and Pharmaceutical Science)).
Trip ‘(title: aged OR middle aged OR elderly AND primary care OR primary health care OR outpatient care) 
(title: pharmacist* OR pharmaceutical care) (title: usual care OR control) (prescribing OR prescription)’, by 
quality
University of York 
Centre for Reviews 
and Dissemination
(aged) OR (‘middle aged’) OR (elderly) AND (prescribing or prescription* or ‘drug prescribing’ or ‘drug 
prescription*’) AND (‘primary care’) OR (‘primary health care’) OR (‘outpatient care’) AND (pharmacist* 
or ‘clinical pharmacist*’ or ‘pharmaceutical care’ OR ‘pharmacist* intervention’ OR ‘clinical pharmacist* 
intervention’)
ISI Web of Science (‘aged’ or ‘middle aged’ or elderly) Timespan=All years, Search language=Auto AND (‘primary care’ or 
‘primary health care’ or ‘outpatient care’) Timespan=All years, Search language=Auto AND (prescribing 
or prescription*) Timespan=All years, Search language=Auto AND (pharmacist* or ‘pharmaceutical care’) 
Timespan=All years, Search language=Auto
Appendix 2. Ongoing and excluded articles reviewed and reasons for exclusion.
Study 
number
Article Reason for exclusion
1. Developing pharmacist-led research to educate and 
sensitive community residents to the inappropriate 
prescription burden in the elderly.
Source: Clinicaltrials.gov
This study is currently ongoing.
Study start date: March 2014.
Estimated study completion date: September 2016.
2. Inappropriate prescription in elderly and polypharmacy 
patients in primary care. PHARM-PC Trial.
Source: Clinicaltrials.gov
This study is not yet open for participant recruitment.
Study start date: October 2014.
Estimated study completion date: April 2016.
3. A pilot study to reduce inappropriate anticholinergic 
prescribing in the elderly.
Source: Clinicaltrials.gov
This study is currently recruiting participants.
Study start date: September 2014.
Estimated study completion date: December 2015.
4. Educational intervention to reduce drug-related 
hospitalizations in elderly primary health care patients.
Source: Clinicaltrials.gov
Emailed author for full paper: 12 December 2014, 10:50 a.m. 
No reply.
Emailed author again on 13 January 2015, 11:35 a.m. No reply.
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Study 
number
Article Reason for exclusion
5. Minimizing risk and maximizing outcomes in geriatric 
patients through integrated clinical pharmacy services 
in an innovative model of community practice.
Source: Clinicaltrials.gov
The recruitment status of this study is unknown because the 
information has not been verified recently. Observational study.
6. Study of whether educational visits to primary care 
professionals improves the quality of care they provide.
Source: Clinicaltrials.gov
Not relevant. The intervention was evaluated using prescribing 
analysis and cost (PACT) data for antidepressant drugs.
7. An intervention study to reduce the use and impact 
of potentially inappropriate medications among older 
adults.
Source: Clinicaltrials.gov
Emailed author for full paper: 12 December 2014, 11:55 a.m.
Author replied on 12 December 2014, 5 p.m. with the following 
statement:
‘Unfortunately our trial did not involve a pharmacist 
intervention so would not be relevant for your review’.
8. Pharmacist-led medicines management outpatient 
service
Source: Clinicaltrials.gov
Emailed author for full paper: 12 December 2014, 12:05 p.m.
Author replied on 5 January 2015 with the following comment: 
‘The Medicines Management Outpatient Service research is 
currently in progress therefore, unfortunately it is not possible 
to share details at this stage’.
9. Rationalisation of polypharmacy in the elderly by the 
RASP instrument
Source: Clinicaltrials.gov
Emailed author for full paper: 12 December 2014, 12:24 p.m.
Author replied on 13 January 2015 with following comment: 
‘I am afraid that our manuscript concerning the RASP study in 
hospital setting is still in the makings. We are currently finishing 
it as we speak.
Afterwards we will normally finish a short proof-of-concept 
study, which was performed in primary care’.
10. Randomized controlled trial of enhanced pharmacy 
care in older veteran outpatients
Source: Clinicaltrials.gov
Emailed author for full paper: 12 December 2014, 12:30 p.m. 
No response.
Emailed author again on 13 January 2015 at 11:50 a.m. No 
response.
11. Preventing falls through enhanced pharmaceutical care
Source: Clinicaltrials.gov
Full article obtained.
The purpose of this study was to assess the effects of a 
community pharmacy–based falls prevention programme.
12. Lipton H, Bero L, Bird JA, et al. The impact of clinical 
pharmacists’ consultations on physicians’ geriatric drug 
prescribing. A randomized controlled trial. Med Care 
1992; 30(7): 646–658.
Full article obtained.
Intervention in secondary care.
Not a validated tool in 1992.
13. Elderly people still given inappropriate drugs. 
Pharmaceut J 2006; 276(7384): 62.
Report from the Pharmaceutical Journal.
14. Vinks T, Egberts T, De Lange T, et al. Pharmacist-based 
medication review reduces potential drug-related 
problems in the elderly: the SMOG controlled trial. 
Drugs Aging 2009; 26(2): 123–133.
Full article obtained.
No screening tool used.
Medication review used. Drug-related problems were identified 
and validated by reference to national prescribing guidelines 
such as the practice standards of Dutch general practitioners 
(GPs) as well as therapeutic handbooks.
15. Allard J, Hebert R, Rioux M, et al. Efficacy of a clinical 
medication review on the number of potentially 
inappropriate prescriptions prescribed for community-
dwelling elderly people. CMAJ 2001; 164(9): 1291–1296.
Full article obtained.
Potentially inappropriate prescriptions (PIPs) were identified 
from a list of PIPs developed by the Quebec Committee on 
Drug Use in the Elderly. Although generated by a panel of 
experts, this list has never been validated with empirical data.
16. The Community Pharmacy Medicines Management 
Project Evaluation Team. The MEDMAN study: a 
randomized controlled trial of community pharmacy-
led medicines management for patients with coronary 
heart disease. Fam Pract 2007; 24: 189–200.
Full article obtained.
No screening tool used.
17. Castelino RL, Hilmer SN, Bajorek BV, et al. Drug 
Burden Index and potentially inappropriate medications 
in community-dwelling older people: the impact of 
Home Medicines Review. Drugs Aging 2010; 27(2): 
135–148.
From abstract: A retrospective analysis of medication reviews. 
No control group.
Full article not required.
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18. Cowper PA, Weinberger M, Hanlon JT, et al. The 
cost-effectiveness of a clinical pharmacist intervention 
among elderly outpatients. Pharmacotherapy 1998; 
18(2): 327–332.
Full article obtained.
Cost analysis of a previously reported randomised controlled 
trial. (A randomised controlled trial of a clinical pharmacist 
intervention to improve inappropriate prescribing in elderly 
outpatients with polypharmacy. Hanlon et al. 1996. This paper 
was included in our final review.)
19. Davis RG, Hepfinger CA, Sauer KA, et al. 
Retrospective evaluation of medication appropriateness 
and clinical pharmacist drug therapy recommendations 
for home-based primary care veterans. Am J Geriatr 
Pharmacother 2007; 5(1): 40–47.
Full article obtained: Hard copy only.
Retrospective analysis.
No control group.
20. Denneboom W, Dautzenberg MG, Grol R, et al. 
Treatment reviews of older people on polypharmacy 
in primary care: cluster controlled trial comparing two 
approaches. Br J Gen Pract 2007; 57(542): 723–731.
Full article obtained.
Treatment review only.
No screening tool used.
21. Faya S. Pharmaceutical care for elderly patients in 
community pharmacy: analysis and evaluation of community 
pharmacist interventions in the Randomised Evaluation of 
Shared Prescribing for Elderly People in the Community over 
Time (RESPECT) Study. Bradford: University of Bradford, 
2009.
Paper produced as part of PhD thesis. Thesis obtained.
22. Fletcher J, Hogg W, Farrell B, et al. Effect of 
nurse practitioner and pharmacist counselling on 
inappropriate medication use in family practice. Can 
Fam Physician 2012; 58(8): 862–868.
Full article obtained.
This study had no control group.
23. Goodyear-Smith F. Appropriate medications: 
prescription and use in primary care. J Prim Health Care 
2013; 5(3): 178–179.
Full article obtained.
Not relevant: Editorial review.
24. Grymonpre RE, Williamson DA and Montgomery 
PR. Impact of a pharmaceutical care model for non-
institutionalised elderly: results of a randomised, 
controlled trial. Int J Pharm Pract 2001; 9: 235–241.
Full article obtained.
Not related to inappropriate prescribing.
25. Howard R, Rodgers S, Avery AJ, et al. Description 
and process evaluation of pharmacists’ interventions 
in a pharmacist-led information technology-enabled 
multicentre cluster randomised controlled trial 
for reducing medication errors in general practice 
(PINCER trial). Int J Pharm Pract 2014; 22(1): 59–68.
Full article obtained.
Pharmacist’s recommendations to manage individual cases of 
hazardous medicines management.
No screening tool used.
26. Kaufman MB, Brodin KA and Sarafian A. Effect of 
prescriber education on the use of medications 
contraindicated in older adults in a managed Medicare 
population. J Manag Care Pharm 2005; 11(3): 211–219.
Full article obtained.
This was a before and after study. No control group.
27. Krska J, Cromarty JA, Arris F, et al. Pharmacist-led 
medication review in patients over 65: a randomized, 
controlled trial in primary care. Age Ageing 2001; 30(3): 
205–211.
Full article obtained.
The study identified pharmaceutical care issues using 
medication reviews, however, no screening tool used.
28. Kwint HF, Faber A and Bouvy ML. The effect of home 
medication review on the resolution of drug related 
problems and health-related quality of life. Int J Clin 
Pharm 2013; 35(5): 896.
Article obtained.
Poster presented at 41st European Society of Clinical Pharmacy 
symposium on clinical pharmacy: Barcelona, Spain. 29–31 
October 2012.
29. Kwint HF, Faber A, Gussekloo J, et al. Effects of 
medication review on drug-related problems in patients 
using automated drug-dispensing systems: a pragmatic 
randomized controlled study. Drugs Aging 2011; 28(4): 
305–314.
Full article obtained.
Medication review. Implicit and explicit criteria used. Explicit 
criteria consisted of a list of clinical rules based on Dutch 
treatment and prescription guidelines. Implicit criteria for 
identifying Drug-related problems were based on a structural 
assessment by Cipolle according to a rational order of 
indication, effectiveness, safety and compliance.
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30. Lipton HL, Bird JA, Bero LA, et al. Assessing the 
appropriateness of physician prescribing for geriatric 
outpatients: development and testing of an instrument. 
J Pharm Technol 1993; 9(3): 107–113.
Full article obtained: Hard copy only.
This study was carried out in secondary care. It involved the 
development and testing of an instrument for drug therapy 
prescribing problems for geriatric patients.
31. Lund BC, Carnahan RM, Egge JA, et al. Inappropriate 
prescribing predicts adverse drug events in older 
adults. Ann Pharmacother 2010; 44(6): 957–963.
Full article obtained.
Study utilised data from a previous study. (The Veterans 
Affairs Enhanced Pharmacy Outpatient Clinic (EPOC) study: a 
randomised controlled pharmacist–physician intervention trial: 
Kaboli et al. 2004.) Objective: To determine whether an implicit 
measure of inappropriate prescribing can predict ADE risk.
MAI score not segregated between control and intervention group.
32. Martin P, Tamblyn R, Ahmed S, et al. An educational 
intervention to reduce the use of potentially 
inappropriate medications among older adults 
(EMPOWER study): protocol for a cluster randomized 
trial. Trials 2013; 14: 80.
Full article obtained.
Educational intervention. Outcome: Cessation of 
benzodiazepines in the 6 months following receipt of the 
intervention.
No screening tool used.
33. Milos V, Rekman E, Bondesson A, et al. Improving the 
quality of pharmacotherapy in elderly primary care 
patients through medication reviews: a randomised 
controlled study. Drugs Aging 2013; 30(4): 235–246.
Full article obtained.
The majority of the patients in this study were living in nursing 
homes. The goal of medication reviews has been improved 
patient safety and quality of medication use, according to the 
Swedish National Board of Health and Welfare’s indicators for 
good drug therapy in the elderly.
34. Mino-Leon D, Reyes-Morales H, Jasso L, et al. 
Physicians and pharmacists: collaboration to improve 
the quality of prescriptions in primary care in Mexico. 
Int J Clin Pharm 2012; 34(3): 475–480.
Full article obtained.
Aim: To reduce prescription errors for patients with diabetes 
and/or hypertension.
No screening tool used.
35. Morley JE. Inappropriate drug prescribing and 
polypharmacy are major causes of poor outcomes in long-
term care. J Am Med Dir Assoc 2014; 15(11): 780–782.
Not relevant.
Study carried out in long-term care, for example, nursing 
homes.
36. Morrison A and Wertheimer AI. Evaluation of studies 
investigating the effectiveness of pharmacists’ clinical 
services (Structured abstract). Am J Health Syst Pharm 
58(7): 569–577.
Not relevant: systematic review.
37. Reboredo-Garcia S, Mateo CG and Casal-Llorente C. 
Implantation of a program for polymedicated patients 
within the framework of the Galician Strategy for 
Integrated Chronic Care. Aten Primaria 2014; 46(Suppl. 
3): 33–40.
Full article obtained.
Published in Spanish. (A native Spanish speaker was recruited 
to translate the article into English, Dec 2014.)
No control study.
38. Rossi MI, Young A, Maher R, et al. Polypharmacy 
and health beliefs in older outpatients. Am J Geriatr 
Pharmacother 2007; 5(4): 317–323.
Abstract only.
This study contained no control group.
39. Schmader KE, Hanlon JT, Pieper CF, et al. Effects of 
geriatric evaluation and management on adverse drug 
reactions and suboptimal prescribing in the frail elderly. 
Am J Med 2004; 116(6): 394–401.
Full article obtained.
Analysed same patients as inpatient and outpatients.
40. Sellors J, Kaczorowski J, Sellors C, et al. A randomized 
controlled trial of a pharmacist consultation program 
for family physicians and their elderly patients 
(structured abstract). CMAJ 2003; 169(1): 17–22.
Full article obtained.
The intervention focused on drug-related problems. The 
primary end-point measure was a reduction in the daily units of 
medication taken, as a surrogate for optimised drug therapy.
41. Shade MY, Berger AM and Chaperon C. Potentially 
inappropriate medications in community-dwelling older 
adults. Res Gerontol Nurs 7(4): 178–192.
Full article obtained.
This is a systematic review.
42. Teichert M, Luijben SN, Wereldsma A, et al. 
Implementation of medication reviews in community 
pharmacies and their effect on potentially inappropriate 
drug use in elderly patients. Int J Clin Pharm 2013; 35(5): 
719–726.
Full article obtained.
Specifically developed algorithms were used to identify nine 
potentially inappropriate medicines (PIMs) from the HARM 
study.
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43. Wong I, Campion P, Coulton S, et al. Pharmaceutical 
care for elderly patients shared between community 
pharmacists and general practitioners: a randomised 
evaluation. RESPECT (Randomised Evaluation of Shared 
Prescribing for Elderly people in the Community over 
Time. BMC Health Serv Res 2004; 4(1): 11.
Full article obtained.
This paper describes a proposed randomised multiple 
interrupted time series trial design.
44. Zermansky AG, Petty DR, Raynor DK, et al. Clinical 
medication review by a pharmacist of patients on 
repeat prescriptions in general practice: a randomised 
controlled trial. Health Technol Assess 2002; 6(20): 1–86.
Full article obtained.
Primary outcome: the number of repeat medication changes 
per patient over a 12-month period. Secondary outcome was 
the effect on the medication costs.
45. Basger BJ, Moles RJ and Chen TF. Impact of an 
enhanced pharmacy discharge service on prescribing 
appropriateness criteria: a randomised controlled trial. 
Int J Clin Pharm 2015; 37: 1194–1205.
Full article obtained.
This study was performed in a small private hospital. (Not a 
primary care study.)
46. Rose O, Waltering I, John C, et al. The WestGem 
study; medication management in the elderly. Int J Clin 
Pharm 2015; 37(2): 405–406.
Abstract only obtained.
The WestGem-Study is still going on. Results will be published 
by the end of 2015.
47. Verdoorn S, Kwint HF, Faber A, et al. Majority of drug-
related problems identified during medication review 
are not associated with STOPP/START criteria. Eur J 
Clin Pharmacol 2015; 71(10): 1255–1262.
Full article obtained.
This study has no control group.
48. Bregnhøj L, Thirstrup S, Kristensen MB, et al. 
Combined intervention programme reduces 
inappropriate prescribing in elderly patients exposed 
to polypharmacy in primary care. Eur J Clin Pharmacol 
2009; 65: 199–207.
Full article obtained.
This was not a pharmacist-led study. The pharmacist analysed 
the patients’ prescription and medical history and proposed 
changes in their medication. The pharmacist and clinical 
pharmacologist discussed these recommendations; however, 
it was the responsibility of the clinical pharmacologist what 
was finally recommended. The pharmacist forwarded the 
feedback to the physicians. The clinical pharmacologists 
contacted the physicians by telephone to discuss any 
uncertainties concerning the recommendations given. The 
clinical pharmacologists delivered the interactive educational 
interventions.
49. Monane M, Matthias D, Nagle B, et al. Improving 
prescribing patterns for the elderly through an online 
drug utilization review intervention: a system linking 
the physician, pharmacist, and computer. JAMA 1998; 
280(14): 1249–1252.
*Handsearched
Full article obtained.
This study has no control group.
50. Fick DM, Maclean JR, Rodriguez NA, et al. A 
randomized study to decrease the use of potentially 
inappropriate medicines among community dwelling 
older adults in a south-eastern managed care 
organisation. Am J Manag Care 2004; 10(11 Pt 1): 
761–768.
*Handsearched
Full article obtained.
Pharmacists suggested a list of potentially inappropriate 
medicine alternative medicines and performed a peer review 
of the drugs to be included in the intervention and their 
corresponding alternative medications.
Not a pharmacist-led intervention.
51. Bucci C, Jackevicius C, McFarlane K, et al. Pharmacist’s 
contribution in a heart function clinic: patient 
perception and medication appropriateness. Can J 
Cardiol 2003; 19(4): 391–396.
*Handsearched
Full article obtained.
This pharmacist intervention was carried out at the heart 
function clinic at Toronto General Hospital. Interventions 
carried out in secondary care were not included in the review.
52. Meredith S, Feldman P, Frey D, et al. Improving 
medication use in newly admitted home healthcare 
patients: a randomized controlled trial. J Am Geriatr Soc 
2002; 50: 1484–1491.
*Handsearched
Full article obtained.
There was no validated screening tool used in this study and 
potentially inappropriate prescribing was not measured as an 
outcome.
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53. Avorn J and Soumerai SB. Improving drug-therapy 
decisions through educational outreach. A randomized 
controlled trial of academically based ‘detailing’. N Engl 
J Med 1983; 308(24): 1457–1463.
*Handsearched
Full article obtained.
The three target drugs were selected on the basis of an 
analysis of national prescribing practices, for example, 
Medicaid prescribing records and evidence from published 
controlled clinical trials. There was no screening tool used in 
the intervention, and the target population was not specifically 
aimed at those aged over 65 years.
Appendix 2. (Continued)
Appendix 3. PRISMA checklist.
Section/topic # Checklist item Reported 
on page #
TITLE  
Title 1 Identify the report as a systematic review, meta-analysis or both. 1
ABSTRACT  
Structured 
summary
2 Provide a structured summary including as applicable: background, objectives, data sources, 
study eligibility criteria, participants and interventions, study appraisal and synthesis 
methods, results, limitations, conclusions and implications of key findings, systematic review 
registration number.
2–3
INTRODUCTION  
Rationale 3 Describe the rationale for the review in the context of what is already known. 4–6
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes and study design (PICOS).
6
METHODS  
Protocol and 
registration
5 Indicate if a review protocol exists, if and where it can be accessed (e.g. web address), and, if 
available, provide registration information including registration number.
N/A
Eligibility criteria 6 Specify study characteristics (e.g. PICOS, length of follow-up) and report characteristics 
(e.g. years considered, language and publication status) used as criteria for eligibility, giving 
rationale.
7
Information 
sources
7 Describe all information sources (e.g. databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.
6
Search 8 Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated.
6
Study selection 9 State the process for selecting studies (i.e. screening, eligibility, included in systematic 
review, and, if applicable, included in the meta-analysis).
7
Data collection 
process
10 Describe method of data extraction from reports (e.g. piloted forms, independently and in 
duplicate) and any processes for obtaining and confirming data from investigators.
7–8
Data items 11 List and define all variables for which data were sought (e.g. PICOS, funding sources) and 
any assumptions and simplifications made.
6–8
Risk of bias in 
individual studies
12 Describe methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis.
8
Summary measures 13 State the principal summary measures (e.g. risk ratio, difference in means). N/A
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g. I2) for each meta-analysis.
N/A
Page 1 of 2: risk of 
bias across studies
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g. 
publication bias, selective reporting within studies).
N/A
Additional analyses 16 Describe methods of additional analyses (e.g. sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.
N/A
RESULTS  
Study selection 17 Give numbers of studies screened, assessed for eligibility and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.
9, 26
Study 
characteristics
18 For each study, present characteristics for which data were extracted (e.g. study size, 
PICOS, follow-up period) and provide the citations.
9–12, 
27–38
 (Continued)
18 SAGE Open Medicine
Section/topic # Checklist item Reported 
on page #
Risk of bias within 
studies
19 Present data on risk of bias of each study, and, if available, any outcome level assessment 
(see Item 12).
12, 39–40
Results of individual 
studies
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group and (b) effect estimates and confidence intervals, 
ideally with a forest plot.
12, 39–40
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.
N/A
Risk of bias across 
studies
22 Present results of any assessment of risk of bias across studies (see Item 15). N/A
Additional analysis 23 Give results of additional analyses, if done (e.g. sensitivity or subgroup analyses, meta-
regression (see Item 16)).
N/A
DISCUSSION  
Summary of 
evidence
24 Summarize the main findings including the strength of evidence for each main outcome, 
consider their relevance to key groups (e.g. healthcare providers, users and policy makers).
13–14
Limitations 25 Discuss limitations at study and outcome level (e.g. risk of bias) and at review-level (e.g. 
incomplete retrieval of identified research, reporting bias).
19
Conclusions 26 Provide a general interpretation of the results in the context of other evidence and 
implications for future research.
15–20
FUNDING  
Funding 27 Describe sources of funding for the systematic review and other support (e.g. supply of 
data), role of funders for the systematic review.
N/A
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; N/A: not applicable.
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